Japanese (NIKKEI) Biotech Industry Analysis
- 7D-6.4%
- 3M-21.0%
- 1Y-46.8%
- YTD-12.2%
Over the last 7 days, the Biotech industry has dropped 7.3%, driven by declines in PeptiDream and Takara Bio of 6.1% and 5.5%, respectively. Meanwhile, CanBas actually outperformed within the industry, gaining 21% in the last week. However, the industry is down 47% over the past year.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Tue, 25 Jan 2022 | JPÂ¥1.1t | JPÂ¥163.5b | -JPÂ¥5,447,358,000.00 | 16.3x |
| Thu, 23 Dec 2021 | JPÂ¥1.3t | JPÂ¥163.5b | -JPÂ¥5,447,524,000.00 | 18.3x |
| Sat, 20 Nov 2021 | JPÂ¥1.3t | JPÂ¥159.5b | -JPÂ¥8,764,958,000.00 | 20.7x |
| Mon, 18 Oct 2021 | JPÂ¥1.4t | JPÂ¥147.6b | -JPÂ¥12,269,440,000.00 | 23.8x |
| Wed, 15 Sep 2021 | JPÂ¥1.7t | JPÂ¥147.9b | -JPÂ¥14,140,440,000.00 | 25.8x |
| Fri, 13 Aug 2021 | JPÂ¥1.7t | JPÂ¥148.3b | -JPÂ¥14,096,440,000.00 | 23.9x |
| Tue, 08 Jun 2021 | JPÂ¥1.8t | JPÂ¥130.4b | -JPÂ¥17,249,632,000.00 | 37.7x |
| Mon, 01 Mar 2021 | JPÂ¥1.8t | JPÂ¥112.5b | -JPÂ¥20,970,087,000.00 | 109.4x |
| Thu, 03 Dec 2020 | JPÂ¥1.9t | JPÂ¥90.4b | -JPÂ¥27,284,135,000.00 | 231x |
| Sun, 06 Sep 2020 | JPÂ¥1.8t | JPÂ¥82.0b | -JPÂ¥25,982,602,000.00 | 141.7x |
| Wed, 10 Jun 2020 | JPÂ¥1.8t | JPÂ¥80.7b | -JPÂ¥31,890,297,000.00 | 90.6x |
| Tue, 03 Mar 2020 | JPÂ¥1.3t | JPÂ¥77.2b | -JPÂ¥30,683,316,000.00 | 65.2x |
| Fri, 06 Dec 2019 | JPÂ¥1.6t | JPÂ¥79.8b | -JPÂ¥25,898,343,000.00 | 145.5x |
| Mon, 09 Sep 2019 | JPÂ¥1.6t | JPÂ¥79.1b | -JPÂ¥17,932,601,000.00 | 67.1x |
| Sun, 02 Jun 2019 | JPÂ¥1.6t | JPÂ¥78.1b | -JPÂ¥15,751,630,000.00 | 78.4x |
| Wed, 06 Mar 2019 | JPÂ¥1.6t | JPÂ¥75.3b | -JPÂ¥17,055,901,000.00 | 82.2x |
88.1x
Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 16.4x which is lower than its 3-year average PE of 91.0x. It appears they believe that earnings will not grow as fast as they have historically.
Past Earnings Growth: The earnings for companies in the Biotechs industry have improved over the last three years, and revenues for these companies have grown 30% per year. This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Japanese Biotech industry?
| Biotech | -6.43% | |
Industry PE: Investors are most optimistic about the Biotech industry even though it's trading below its 3-year average PE ratio of 91.0x. However analysts are expecting annual earnings growth of 10%, which is lower than the prior year's growth of 399% per year. So the market might believe that analysts are underestimating future growth.
Forecasted Growth: Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 10% over the next 5 years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4884 Kringle Pharma | JPÂ¥698.00 | 1.5% +JPÂ¥91.8m | -40.3% | PS11.1x |